Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those

Reid, MichelleBalcı, SerdarBağcı, PelinSaka, BurcuPehlivanoğlu, BurçinErbarut Seven, İpekBaştürk, OlcaAdsay, N. Volkan2020-04-162020-04-162020Reid, M., Balcı, S., Bağcı, P., Saka, B., Pehlivanoğlu, B., Erbarut Seven, İ. ... Adsay, N. V. (2020). Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) içinde (1673-1673. ss.). Los Angeles, CA, February 29-March 05, 2020.0893-39521530-0285https://hdl.handle.net/20.500.12511/5129Background: Grading of linear parameters into meaningful (clinically relevant) clusters is a well-known challenge. Recently several groupshave proposed to change the Ki67 index cut-off for grade 1 (G1) category for PanNETs from < 3% to < 5%. This proposal presupposes thatthe cases with Ki67 index of 3-5% are NOT clinically different than the 0-3% group and thus can be lumped together with the current G1 (0-3% cases), instead of their current home in the G2 category (> 3%).eninfo:eu-repo/semantics/embargoedAccessPancreatic NeuroendocrineClinicopathologicKi67 IndexIs it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%Conference Object33Supplement: 216731673Q1